Clinical Evidence

1. Combined assessment of 3q26 amplification and promoter methylation in patients with high grade cervical lesions show age specific differences, 2019 (Beiersdorf et al.)

2. Gain of Chromosomal Region 3q26 as a Prognostic Biomarker for High-Grade Cervical Intraepithelial Neoplasia: Literature Overview and Pilot Study, 2019 (Koeneman et al.)

3. Different amplification patterns of 3q26 and 5p15 regions in cervical intraepithelial neoplasia and cervical cancer, 2018 (Kudela et al.)

4. Amplification of the 3q chromosomal region as a specific marker in cervical cancer, 2015 (Wright et al.)

5. Human Telomerase Gene and High-Risk Human Papillomavirus Infection are Related to Cervical Intraepithelial Neoplasia, 2015 (Zhao et al.)

6. Clinical Role of the Detection of Human Telomerase RNA Component Gene Amplification by Fluorescence in situ Hybridization on Liquid-Based Cervical Samples: Comparison with Human Papillomavirus-DNA Testing and Histopathology, 2015 (Zappacosta et al.)

7. Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High-Grade Cervical Lesions and Invasive Cancer, 2010 (Jiang et al.)

8. Genomic Amplification of the Human Telomerase Gene (TERC et al.) in Pap Smears Predicts the Development of Cervical Cancer, 2005 (Heselmeyer-Haddad et al.)